Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Circulation Research

• Publication date

  2012-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/RES.0b013e31824da8adPMID 22383708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study

  2011cited by this paper
• Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

  2011cited by this paper
• Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data

  2011cited by this paper
• Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

  2011cited by this paper
• Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk

  2011cited by this paper
• Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

  2011cited by this paper
• Practice of Epidemiology Problems With Risk Reclassification Methods for Evaluating Prediction Models

  2011cited by this paper
• Risk factors and interventions with statistically significant tiny effects.

  2011cited by this paper
• Commentary: Reporting standards are needed for evaluations of risk reclassification.

  2011cited by this paper
• Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis

  2011cited by this paper
• Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.

  2011cited by this paper
• Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

  2011cited by this paper
• Use of reclassification for assessment of improved prediction: an empirical evaluation.

  2011cited by this paper
• 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2010cited by this paper
• Hyperuricemia and coronary heart disease: A systematic review and meta‐analysis

  2010cited by this paper
• Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids

  2010cited by this paper
• C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

  2010cited by this paper
• Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-Wide Association Meta-analysis Involving More Than 22 000 Cases and 60 000 Controls

  2010cited by this paper
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease

  2010cited by this paper
• ACCF/AHA Practice Guideline Practice Guidelines 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults

  2010cited by this paper
• 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2010cited by this paper
• Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.

  2009cited by this paper
• Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association

  2009cited by this paper
• Major lipids, apolipoproteins, and risk of vascular disease.

  2009cited by this paper
• B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies

  2009cited by this paper
• Assessment of claims of improved prediction beyond the Framingham risk score.

  2009cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease.

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Why Current Publication Practices May Distort Science

  2008cited by this paper
• Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review

  2008cited by this paper
• C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men

  2008cited by this paper
• C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.

  2007cited by this paper
• Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction

  2007cited by this paper
• Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

  2007cited by this paper
• Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence.

  2007cited by this paper
• Selection in Reported Epidemiological Risks: An Empirical Assessment

  2007cited by this paper
• The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases

  2007cited by this paper
• The Emergence of Networks in Human Genome Epidemiology: Challenges and Opportunities

  2007cited by this paper
• Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study.

  2007cited by this paper
• Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'.

  2006cited by this paper
• Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations

  2006cited by this paper
• Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials.

  2005cited by this paper
• Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

  2005cited by this paper
• A network of investigator networks in human genome epidemiology.

  2005cited by this paper
• Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

  2004cited by this paper
• Inflammation as a Cardiovascular Risk Factor

  2004cited by this paper
• Author Contributions: JGW, KDMJ,

  2004cited by this paper
• Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.

  2004cited by this paper
• MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

  2002cited by this paper
• Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis.

  2001cited by this paper
• Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.

  1998cited by this paper
• Prediction of coronary heart disease using risk factor categories.

  1998cited by this paper
• For Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. for Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. Homocysteine Level and Coronary Heart Disease Incidence: a Systematic Review and Meta-analysis

  year unknowncited by this paper

• Understanding the Metabolic Fingerprint of Muscle Aging

  2025cites this paper
• Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis.

  2025cites this paper
• Negative findings but positive contributions in cardiovascular research.

  2023cites this paper
• Risk Assessment of Cardiovascular Diseases Using kNN and Decision Tree Classifier

  2022cites this paper
• Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica

  2022cites this paper
• Metabolic subgroups and cardiometabolic multimorbidity in the UK Biobank

  2021cites this paper
• Implications of the ACC/AHA risk score for prediction of heart failure: the Rotterdam Study

  2021cites this paper
• 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

  2021cites this paper
• IGFBP-1 and IGFBP-2 are associated with a decreased pulse-wave velocity in young, healthy adults

  2021cites this paper
• High baseline fetuin-A levels are associated with lower atherosclerotic plaque progression as measured by 3D ultrasound

  2021cites this paper
• Internal-external cross-validation helped to evaluate the generalizability of prediction models in large clustered datasets.

  2021cites this paper
• Depression and biomarkers of cardiovascular disease

  2021cites this paper
• 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

  2021cites this paper
• Genetic Biomarkers of Psychiatric Disease: Discriminating Bipolar Disorder From Major Depressive Disorder With Polygenic Risk Scores

  2020cites this paper
• Natural products: The role and mechanism in low‐density lipoprotein oxidation and atherosclerosis

  2020cites this paper
• On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management

  2020cites this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

  2020cites this paper
• Immunometabolic and Cellular Traits in Cardiovascular Disease

  2019cites this paper
• Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort

  2019cites this paper
• Low density lipoprotein-induced lipid accumulation is a key phenomenon of atherogenesis at the arterial cell level

  2019cites this paper
• 4-Hydroxyglutamate is a novel predictor of pre-eclampsia

  2019cites this paper
• Diagnosis: From classification to prediction.

  2019cites this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

  2019cites this paper
• Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?

  2019cites this paper
• Evaluating Longitudinal Associations Between Depressive Symptoms, Smoking, and Biomarkers of Cardiovascular Disease in the CARDIA Study

  2019cites this paper
• Interleukin 6 trans-signalling and risk of future cardiovascular events

  2018cites this paper
• Modified lipoproteins as biomarkers of atherosclerosis.

  2018cites this paper
• Title Increased levels of circulating fatty acids are associated with protective effects against future cardiovascular events in non-diabetics

  2018cites this paper
• New technological devices for the assessment of systemic inflammation in the primary prevention of cardiovascular disease

  2017cites this paper
• Predictive model for the development of hypertensive cardiopathy: A prospective cohort study.

  2017cites this paper
• A targeted approach toward more accurate assessment of hypertension

  2017cites this paper
• Increased Levels of Circulating Fatty Acids Are Associated with Protective Effects against Future Cardiovascular Events in Nondiabetics.

  2017cites this paper
• Novel Risk Markers and Risk Assessments for Cardiovascular Disease

  2017cites this paper
• Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers

  2017cites this paper
• Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event

  2017cites this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2017cites this paper
• Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica

  2016cites this paper
• Participant‐Reported Health Status Predicts Cardiovascular and All‐Cause Mortality Independent of Established and Nontraditional Biomarkers: Evidence From a Representative US Sample

  2016influential citation
• Metabolic profiling–multitude of technologies with great research potential, but (when) will translation emerge?

  2016cites this paper
• The interaction between systemic inflammation and psychosocial stress in the association with cardiac troponin elevation: A new approach to risk assessment and disease prevention

  2016influential citation
• Worldwide Exposures to Cardiovascular Risk Factors and Associated Health Effects: Current Knowledge and Data Gaps

  2016cites this paper
• Exposure‐wide epidemiology: revisiting Bradford Hill

  2016cites this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice.

  2016cites this paper
• JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda

  2016cites this paper
• Asociación entre niveles patológicos de amiloide A sérico y periodontitis

  2016cites this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2016cites this paper
• A systems biology approach for the study of smoking and myocardial infarction

  2015cites this paper
• How Medical Practice Has Gone Wrong: Causes of the Lack-of-Reproducibility Crisis in Medical Research

  2015cites this paper
• Application of credibility ceilings probes the robustness of meta-analyses of biomarkers and cancer risk.

  2015cites this paper
• Distinguishing bipolar from unipolar depression: the importance of clinical symptoms and illness features

  2015cites this paper
• Uric acid and cardiovascular disease risk reclassification: Findings from NHANES III

  2015cites this paper
• External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination.

  2015cites this paper
• Weight-of-evidence evaluation of short-term ozone exposure and cardiovascular effects

  2014cites this paper
• Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?

  2014cites this paper
• Weight-of-evidence evaluation of long-term ozone exposure and cardiovascular effects

  2014cites this paper
• Biomarkers of tobacco smoke exposure.

  2014cites this paper
• Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature.

  2014cites this paper
• Cardiac biomarkers in the prediction of risk in the non‐cardiac surgery setting

  2014cites this paper
• Biomarker Tests for Risk Assessment in Coronary Artery Disease: Will They Change Clinical Practice?

  2013cites this paper
• Postoperative B-type Natriuretic Peptide for Prediction of Major Cardiac Events in Patients Undergoing Noncardiac Surgery: Systematic Review and Individual Patient Meta-analysis

  2013cites this paper
• Diagnosis: Biomarkers of cardiovascular outcomes—bonanza or bias?

  2013cites this paper
• Perioperative cardiac biomarkers: the utility and timing

  2013cites this paper
• A Study of the Effect of Isoproterenol on Red Blood Cell Concentrations of Adenine Nucleotides in a Freely Moving Rat Model In Vivo

  2013cites this paper
• Biomarkers, Cardiovascular Disease, and Hypertension

  2013cites this paper
• Desideratum for Evidence Based Epidemiology

  2013cites this paper
• Proteomics and metabolomics in renal transplantation‐quo vadis?

  2013cites this paper
• Validity of self-reported adult secondhand smoke exposure

  2013cites this paper
• Bias in associations of emerging biomarkers with cardiovascular disease.

  2013cites this paper
• Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk.

  2012cites this paper
• The importance of potential studies that have not existed and registration of observational data sets.

  2012cites this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2012cites this paper